trial
as of 2026-07-01A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
NCTId NCT04524403
at a glance
Phase 2 · Completed
Enrollment 150 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2022-07-29
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
150 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-09-09
Primary completion
2022-07-29
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Corcept TherapeuticsLead Sponsor
Investigators
1
Kavita Juneja, MDStudy Director
Sites
40 total
Bentonville, United StatesLittle Rock, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesOceanside, United StatesPico Rivera, United StatesRancho Cucamonga, United StatesSan Diego, United StatesStanford, United StatesMiami, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
150
Phase
PHASE2
Primary Completion Date
2022-07-29
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person